Bausch + Lomb Corporation (BLCO) Stock Price
BLCOStock
$16.49+10.97%52W
Market Cap$5.89B
P/E—
PEG Ratio0.89
Div yield—
Beta0.56
BLCO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-11.22%
Price vs S&P 500 (4W)-0.52%
PEG Ratio0.89
VGM Score59.12
BLCO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.16 | $0.16 | -0.34%(-$0.00) | |
| Q1 2026 | $0.05 | $0.08 | +49.17%(+$0.03) | |
| Q4 2025 | $0.36 | $0.32 | -10.30%(-$0.04) | |
| Q3 2025 | $0.16 | $0.18 | +11.91%(+$0.02) | |
| Q2 2025 | $0.08 | $0.07 | -16.89%(-$0.01) |
BLCO Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.61
3.61
3.67
3.67
Industry Peers — Ophthalmic Goods(8)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
BLCOBausch + Lomb Corporation | B | D | B | — | -2.7% | 8.4% | — | $16.49 |
| ALCAlcon Inc. Ordinary Shares | C | C | C | 34.1x | 2.9% | 8.8% | 0.3% | $66.18 |
| COOThe Cooper Companies, Inc. Common Stock | B | B | C | 29.4x | 6.9% | 11.0% | 0.0% | $57.94 |
| WRBYWarby Parker Inc. | D | B | C | 1711.4x | 2.1% | 17.2% | — | $23.34 |
| EYENational Vision Holdings, Inc. Common Stock | A | D | C | 46.6x | 5.7% | 3.0% | — | $17.43 |
| STAAStaar Surgical Co | D | B | C | — | 1.1% | 7.9% | — | $21.27 |
| RXSTRxSight, Inc. Common Stock | B | C | D | — | -17.4% | 55.7% | — | $4.51 |
| LUCYInnovative Eyewear, Inc. Common Stock | B | A | D | — | -88.9% | 113.5% | — | $0.79 |
| LUCYWInnovative Eyewear, Inc. Series A Warrants 8/16/27 | — | — | F | — | — | — | — | $0.03 |
About Bausch + Lomb Corporation
Bausch & Lomb is one of the largest US vision care companies, operating three segments: vision care (contact lenses with ~10% market share, plus brands like Biotrue and Lumify), surgical devices for ophthalmic procedures, and ophthalmic pharmaceuticals. The company was spun off from Bausch Health in 2022 and maintains the industry's largest portfolio of eye care prescriptions, with over 100 products. This diversified portfolio across consumer, surgical, and pharmaceutical markets provides exposure to multiple customer segments within ophthalmology.